Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.

Ringborg U, von Braun J, Celis J, Berns A, Baumann M, Albreht T, Abou-Zeid N, Bagnato V, Brandts C, Chen CJ, di Pietro M, Dosanjh M, Dubois T, Eggermont A, Eggert A, Ernberg I, Faithfull S, Förner J, Fröhling S, Heitor M, Hood L, Jiang W, Jönsson B, Kannan R, Leptin M, Li S, Lindgren P, Lowy D, Ma J, Markham A, Nagy P, Oberst S, Parker MI, Rodin D, Ryan K, Schüz J, Sullivan R, Tabernero J, Turkson P, Várhelyi O, Varmus H, Wang C, Weiderpass E, Wilking N.

Open source

DOI
10.1002/1878-0261.70179
Published
2025-12-15
Container
Mol Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/1878-0261.70179,
  title = {Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.},
  author = {Ringborg U and  von Braun J and  Celis J and  Berns A and  Baumann M and  Albreht T and  Abou-Zeid N and  Bagnato V and  Brandts C and  Chen CJ and  di Pietro M and  Dosanjh M and  Dubois T and  Eggermont A and  Eggert A and  Ernberg I and  Faithfull S and  Förner J and  Fröhling S and  Heitor M and  Hood L and  Jiang W and  Jönsson B and  Kannan R and  Leptin M and  Li S and  Lindgren P and  Lowy D and  Ma J and  Markham A and  Nagy P and  Oberst S and  Parker MI and  Rodin D and  Ryan K and  Schüz J and  Sullivan R and  Tabernero J and  Turkson P and  Várhelyi O and  Varmus H and  Wang C and  Weiderpass E and  Wilking N.},
  year = {2026},
  journal = {Mol Oncol},
  doi = {10.1002/1878-0261.70179},
  url = {https://doi.org/10.1002/1878-0261.70179}
}

RIS

TY  - JOUR
TI  - Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.
AU  - Ringborg U
AU  -  von Braun J
AU  -  Celis J
AU  -  Berns A
AU  -  Baumann M
AU  -  Albreht T
AU  -  Abou-Zeid N
AU  -  Bagnato V
AU  -  Brandts C
AU  -  Chen CJ
AU  -  di Pietro M
AU  -  Dosanjh M
AU  -  Dubois T
AU  -  Eggermont A
AU  -  Eggert A
AU  -  Ernberg I
AU  -  Faithfull S
AU  -  Förner J
AU  -  Fröhling S
AU  -  Heitor M
AU  -  Hood L
AU  -  Jiang W
AU  -  Jönsson B
AU  -  Kannan R
AU  -  Leptin M
AU  -  Li S
AU  -  Lindgren P
AU  -  Lowy D
AU  -  Ma J
AU  -  Markham A
AU  -  Nagy P
AU  -  Oberst S
AU  -  Parker MI
AU  -  Rodin D
AU  -  Ryan K
AU  -  Schüz J
AU  -  Sullivan R
AU  -  Tabernero J
AU  -  Turkson P
AU  -  Várhelyi O
AU  -  Varmus H
AU  -  Wang C
AU  -  Weiderpass E
AU  -  Wilking N.
PY  - 2026
JO  - Mol Oncol
DO  - 10.1002/1878-0261.70179
UR  - https://doi.org/10.1002/1878-0261.70179
ER  -

APA

U, R., J, V. B., J, C., A, B., M, B., T, A., N, A., V, B., C, B., CJ, C., M, D. P., M, D., T, D., A, E., A, E., I, E., S, F., J, F., S, F., M, H., L, H., W, J., B, J., R, K., M, L., S, L., P, L., D, L., J, M., A, M., P, N., S, O., MI, P., D, R., K, R., J, S., R, S., J, T., P, T., O, V., H, V., C, W., E, W., & N., W. (2026). Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.. Mol Oncol. https://doi.org/10.1002/1878-0261.70179

Source records